VistaGen Therapeutics, Inc. Shareholder Class Action Lawsuit
January 19, 2026– The law firm of Federman & Sherwood, a national litigation firm representing shareholders and investors in complex securities matters, today announced it has commenced an independent investigation into potential securities law violations by VistaGen Therapeutics, Inc. (“VistaGen” or the “Company”) (NASDAQ: VTGN) on behalf of purchasers of the Company’s common stock.
Details of the Lawsuit Investigation:
Federman & Sherwood’s investigation focuses on whether VistaGen and certain of its officers and directors made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business, operations, clinical development programs, regulatory prospects, and financial condition.
The investigation will examine whether VistaGen’s public statements concerning the timing, results, and regulatory outlook of its key clinical programs, including its depression and anxiety treatment candidates, were accurate and complete. The inquiry also includes whether the Company properly disclosed the risks, potential setbacks, and evolving data from clinical studies in a timely manner that allowed investors to make informed decisions.
In addition, the investigation will assess whether any corrective disclosures relating to clinical results, regulatory feedback, management changes, or financial guidance were followed by declines in the Company’s stock price that may have harmed investors who relied on prior public statements.
Background:
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The Company’s common stock is publicly traded, and in recent periods VistaGen has issued statements regarding its clinical programs, regulatory strategy, and future prospects. Recent developments affecting clinical trial outcomes and regulatory expectations have raised questions about whether the Company fully and accurately informed the market of material risks and outcomes associated with its therapeutic candidates.
What This Means for Investors:
Investors who purchased or otherwise acquired VistaGen Therapeutics, Inc. common stock and believe they suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Email : sec@federmanlaw.com